

 [Read full article](#)

**Article Title:** UPDATE ON CASTRATE RESISTANT PROSTATE CANCER  
**Authors:** MUREȘANU Horia, IOIART Ioan  
**Affiliation:** Department of Urology, Faculty of Medicine, Vest University Vasile Goldiș, Arad  
**Abstract:** Based on the increased understanding of the biochemical pathways that promote castrate resistant prostate cancer (CRPC), this review discusses the mechanisms of resistance to androgen deprivation therapy (ADT) and the potential for targeted therapy.  
**Keywords:** Castrate resistant prostate cancer, androgen receptor, androgen receptor -inhibitors  
**References:** 1. Isaacs JT, Coffey DS. Adaptation vs. selection as the mechanism responsible for castrate resistant prostate cancer. *J Clin Oncol* 1990;8:1521-31.

2. Heidenreich A, Bastian PJ, Bellmunt J et al. Guidelines on prostate cancer 2012. Available at: [http://www.euro.upt.com/pdf/Suppl/2012-01-16/Suppl\\_1.pdf](http://www.euro.upt.com/pdf/Suppl/2012-01-16/Suppl_1.pdf)
3. Prostate Cancer Clinical Trials Working Group. *J Clin Oncol* 2008;26:1148-59
4. Cookson MS, Roth BJ, Dahm P, et al. Castration-Resistant Prostate Cancer: AUA Guideline [http://www.auanet.org/education/continuing-education/2012-01-16/Suppl\\_1.pdf](http://www.auanet.org/education/continuing-education/2012-01-16/Suppl_1.pdf)
5. Lunardi A, Ala U, Epping MT et al. A Co-clinical approach identifies mechanisms and potential therapeutic targets in castrate resistant prostate cancer. *PLoS One* 2012;7:e34811.
6. Stanevsky Y, Tsivian A, Tsivian M. Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation therapy. *Urology* 2011;77:11-18.
7. Knudsen KE and Kelly WK. Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in castrate resistant prostate cancer. *Cancer Res* 2011;71:11-18.
8. Taplin ME, Bubley GJ, Shuster TD, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. *N Engl J Med* 2003;349:26-31.
9. Linja MJ, Savinainen KJ, Saramaki OR, Tammela TL, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor in prostate cancer. *Cancer Res* 2002;62:4760-4.
10. Chi KN, Bjartell A, Dearnaley D, et al. Castration-resistant prostate cancer: from new pathophysiology to novel therapeutic approaches. *Urology* 2011;77:11-18.
11. Attard G, Cooper CS, de Bono JS. Steroid hormone receptors in prostate cancer: a hard habit to break. *Cancer Res* 2008;68:11-18.
12. Schröder FH. Progress in understanding androgen-independent prostate cancer (AIPC): a review of the literature. *Urology* 2003;61:11-18.
13. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. *Cancer Res* 1997 Jan;57:11-18.
14. Stapleton AM, Timme TL, Gousse AE, et al. Primary human prostate cancer cells harboring p53 mutations. *Cancer Res* 2002;62:11-18.
15. Bauer JJ, Sesterhenn IA, Mostofi FK, et al. Elevated levels of apoptosis regulator proteins p53 and bcl-2 in prostate cancer. *Cancer Res* 1997;57:11-18.
16. Theodorescu D, Broder SR, Boyd JC, et al. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in prostate cancer. *Cancer Res* 1997;57:11-18.
17. MacGrogan D, Bookstein R. Tumor suppressor genes in prostate cancer. *Semin Cancer Biol* 1997;7:11-18.
18. Chi KN. Targeting Bcl-2 with oblimersen for patients with hormone refractory prostate cancer. *World J Urol* 2009;21:11-18.
19. Zhang Z, Li M, Wang H, Agrawal S, et al. Antisense therapy targeting MDM2 oncogene in prostate cancer. *Cancer Res* 2002;62:11-18.
20. Verhagen PC, van Duijn PW, Hermans KG, et al. The PTEN gene in locally progressive prostate cancer. *Cancer Res* 2002;62:11-18.
21. Ruijter E, van de Kaa C, Miller G, et al. Molecular genetics and epidemiology of prostate carcinoma. *Cancer Res* 1997;57:11-18.

**\*Correspondence:** Muresanu Horia  
Spitalul Clinic Judetean de Urgenta Arad  
Email: [hmuresanu@gmail.com](mailto:hmuresanu@gmail.com)

---